Company Summary: eXoZymes Inc.

Overview and Core Technology

• eXoZymes Inc. is a pre-revenue biotechnology company focused on developing innovative biomanufacturing platforms using exozymes—engineered enzymes created with AI and bioengineering methods.
• The core platform involves cell-free exozyme biosolutions capable of converting abundant, affordable feedstocks into a broad spectrum of valuable chemicals.
• Exozymes are advanced, engineered enzymes functioning outside of living cells, enabling multi-step biochemical conversions in bioreactors under benign conditions, providing control, efficiency, and scalability advantages over traditional biological or chemical synthesis methods.

Technology and Science

• The company’s approach avoids the limitations of synthetic biology that uses living cells, which are difficult to scale and often produce low yields due to cellular regulation and toxicity.
• The exozymes platform allows multi-step enzymatic reactions in one bioreactor, reducing costs, environmental impact, and purification complexity.
• The platform is modular, programmable for specific applications, and aims to produce natural products, active pharmaceutical ingredients (APIs), nutraceuticals, and biofuels (notably isobutanol for sustainable aviation fuel).

Business Model

• Stage: Development-stage, with no current products on the market or revenue.
• Focus markets: Initially on low-volume, high-value products such as nutraceuticals with pharmaceutical potential and specific projects like isobutanol biofuel.
• Partnerships: Planning to collaborate via licensing, joint ventures, spinouts, and licensing deals. No current sales, marketing, or manufacturing infrastructure.
• Intellectual Property: Holds a portfolio of patents and trade secrets, including exclusive licenses from UCLA covering co-factor regeneration, cannabinoid biosynthesis, and engineered enzymes.

Current Operations & Status

• Employees: Approximately 31 full-time employees (with 11 holding doctoral degrees), primarily in R&D, pilot projects, business development, and administrative functions.
• Facilities: Headquartered in Monrovia, California, leasing ~10,000 sq. ft. of space for laboratories, pilot activities, offices, fermentation, and analytical labs.
• Funding: Secured over $13.6 million in grants from government agencies (DOE, NIH), foundations (Gates Foundation), and private organizations (Shell GCxN). Raised approximately $15.2 million gross in its IPO in November 2024, with net proceeds around $15.2M, used for expansion, staffing, R&D, and debt repayment.

Financial Highlights (as of Dec 31, 2024)

• Revenues: None (company is pre-revenue).
• Net Loss: Approximately $5.86 million for 2024, increased from about $2.04 million in 2023.
• Cash & Equivalents: Approximately $9.72 million (significant increase post-IPO).
• Assets: Total assets of about $13 million; mainly cash and property.
• Liabilities: Total liabilities of about $2.6 million, primarily current payables.
• Shareholders’ Equity: Approximate equity of $10.4 million, with large paid-in capital (~$22.36 million) and accumulated deficit (~$11.94 million).

Market & Customer Data

• Customer base: Not specified; no products or customer revenues yet.
• Revenue (2024): None.
• Employees: Around 31 full-time staff.
• Financial Performance: No revenue, ongoing research and development costs, and net losses.

Summary: eXoZymes Inc. is a biotech platform company innovating in cell-free enzymatic biomanufacturing using AI-engineered exozymes, aiming to produce pharmaceuticals, nutraceuticals, and biofuels more sustainably and cost-effectively. The company is currently in development with no revenue, funded through grants and an IPO, and focusing on strategic partnerships and licensing.